Showing results (1061-1070 of 1,095) with videos related to

Sort By:
Pageof 110
European Urology Oncology|December 6, 2025
Prostate-specific Membrane Antigen Positron Emission Tomography Versus Conventional Imaging for Preoperative Staging High-risk Prostate Cancer Patients Undergoing Surgery for cN0M0 Disease: An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional StudyLorenzo Bianchi, Matteo Droghetti, Calogero Catanzaro, et al.
Science Advances|May 20, 2020
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primatesM Bourdenx, A Nioche, S Dovero, et al.
Lancet (London, England)|February 10, 2023
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trialAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2024
Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)Francesco Passiglia, Angela Listì, Paolo Bironzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancerS Novello, V Torri, C Grohe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH studyF de Marinis, T M Kim, L Bonanno, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2021
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamicsLaura Mezquita, Isabel Preeshagul, Edouard Auclin, et al.
Science Advances|November 7, 2025
NAD<sup>+</sup> reverses Alzheimer's neurological deficits via regulating differential alternative RNA splicing of <i>EVA1C</i>Ruixue Ai, Lipeng Mao, Xurui Jin, et al.
Asian Journal of Urology|April 29, 2024
Transperineal laser ablation of the prostate as a treatment for benign prostatic hyperplasia and prostate cancer: The results of a Delphi consensus projectAndrea Cocci, Marta Pezzoli, Fernando Bianco, et al.
Nature Biotechnology|December 18, 2018
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identificationBrendan Bulik-Sullivan, Jennifer Busby, Christine D Palmer, et al.
Pageof 110